last news

VII Innovation Forum in Andalusia: Bionaturis as a successful case

Victor Infante, Bionaturis CEO, participated November 7th in the VII Innovation Forum in Andalusia, which was held at Chamber of Commerce’s facilities in Jerez (Cadiz). Bionaturis, an international reference in developing and producing biological drugs, was presented as a successful case to attendees.

Established eight years ago, Bionaturis is committed from its very beginning on innovation and thus its work in new production platforms of making biopharmaceuticals allows a more global access to them for both producers and patients. It has been listing at the Spanish MAB since January 2012 and has developed a proprietary production system –Flylife-, which allows the production of second generation vaccines using butterfly larvae.

This business forum is part of the InnoCámaras program, which seeks to foster the competitiveness of the SMEs in the region through innovation. More information of the event click here

November 4th, 2013|Blog english, congress, last news, Press english|Comments Off|

Talents back home

Bionaturis, an international reference company in developing biological vaccines, contributes to recover young talents that had to emigrate out of our borders to start or continue their professional careers.

According to one of the few studies that exist about that, made by the Spanish National Institute of Statistics (INE), between 2000 and 2009, 21% of the Spanish PhDs left Spain to work in another country. The grants cost cuttings and the adjustments of employment in research centres and universities have forced the experts to go out of the country. The overall budget in R&D has decreased more than 40% since 2009.

In view of the situation, Bionaturis bets on “Spanish returnees”. Some of them are part of the young and qualified staff of this company based on innovation and research. For example, Begoña Roibas, now Project Manager at Bionaturis, was working in the National University of Seoul during two years before coming back to Spain. Our Chief Scientific Officer (CSO), Juan Jose Infante, worked also during four years in Washington University (USA). They gained experience abroad and now they´re contributing to the company growth.

If you want to read the full report about our Project Manager, Begoña Roibas, in El Mundo, please click here

Spanish Pharmaceutical industry bets on research

The Spanish pharmaceutical industry keeps betting on research with an investment of 972 million Euros in 2012. Namely, the investment reached 200 million Euros at the biotechnology sector, 20% of the total budget.

The most important allocation -479 million- was dedicated to clinical trials, most of them in clinical phase III. It must be highlighted that the expense in clinical research has increased 86% in the last nine years. 45% of the budget was dedicated to research contracts with hospitals, universities and public institutions, an activity that increased nearly 5% in 2012.

According to the data of the survey made to members of Farmaindustria, the number of R&D hiring decreased 3,6% in relation to 2011. However, the qualification of the employees is getting higher and higher: four out of five are graduates and doctors. In general figures, Spain is the fourth country in Europe in pharmaceutical workforce with nearly 40,000 jobs.

These data show that, in spite of the present economic situation and the measures of control of expenses, the pharmaceutical industry is still one of the main driving forces of  Spanish R&D. 

A multinational veterinarian company will test Bionaturis’s vaccine for salmons

Bionaturis (BNT-MAB), an international reference company developing vaccines for aquiculture, has signed a contract with a multinational veterinarian company to evaluate the efficacy and safety of a FLYLIFE-produced vaccine intended to be used against the most devastating diseases affecting the salmon industry.

During the first half (H1) of 2014 the multinational company will perform in vivo exploratory trials in salmons. The salmon industry is, along with the carp one, one of the biggest aquiculture industries in the world, having reached annual figures greater than 11 billion dollars since 2007. Norway with 33% and Chile with 31% lead world production. Throughout history, several episodes of pandemics, mainly of the ISA (Infectious Salmon Anemia) virus, have generated significant losses. Because of that, the search of new prevention and therapeutic solutions to fight those diseases affecting the sector is one of the salmon industry priorities.

Javier Gallastegui, managing director of Bionaturis, states: “the worldwide positioning we have achieved as a supplier of aquaculture vaccines is confirmed with contracts of this kind. If the trials are successful we could get incomes between 10 and 15 million dollars in royalties in the years following the vaccine launch to the market”.Bionaturis (BNT-MAB), an international reference company developing vaccines for aquiculture, has signed a contract with a multinational veterinarian company to evaluate the efficacy and safety of a FLYLIFE-produced vaccine intended to be used against the most devastating diseases affecting the salmon industry.

During the first half (H1) of 2014 the multinational company will perform in vivo exploratory trials in salmons. The salmon industry is, along with the carp one, one of the biggest aquiculture industries in the world, having reached annual figures greater than 11 billion dollars since 2007. Norway with 33% and […]

Ourofino visits Bionaturis Flylife platform

The Brazilian multinational Ourofino visited last week Bionaturis FLYLIFE manufacturing plant in the Agroindustrial Technological Scientific Park of Jerez (PCTA). Representatives of the Brazilian company knew the details of how FLYLIFE can produce millions of second generation vaccines, particularly suited for the veterinary sector. To date this type of vaccine have not been broadly applied matching the needs of the veterinary sector, but new manufacturing platforms make it possible. Ourofino is currently evaluating alternative production systems as FLYLIFE to achieve leadership positions within the sector.  Ourofino guests were guided by Bionaturis technical staff throughout the plant, knowing in detail the production process of biological active ingredients necessary for vaccines.

Ourofino representatives also participated in the Technical Committee of Biotechnology organized by the Technological Corporation of Andalusia (CTA), in collaboration with Bionaturis.



Bionaturis’ FLYLIFE gala day

About thirty managers belonging to different institutions have visited Bionaturis’  FLYLIFE factory this week. The visit was part of the biotech committee of Corporacion Tecnologica of Andalusia (CTA). Reference people of the biotech sector including members of the Brazilian multinational company Ourofino or Bionaturis’ scientific advisor, professor Vikram Vakharia of Maryland University, among others, have been guided by Bionaturis’ staff to know at first hand how thousands of vaccines can be manufactured in no more than 350 square meters. The secret of Flylife is based on the use of butterfly caterpillars as natural factories to get these cutting-edge vaccines, allowing that more people and producers all over the world may have access to them.

About the visit, Javier Gallastegui -managing director of the company- claims “welcoming these personalities and friends and showing them how we take those vaccines to the world from Jerez is an honor for us”. Nowadays, several multinational companies that work in veterinarian field are evaluating vaccines produced by FLYLIFE technology, representing an outstanding milestone for Spanish Biotechnology.

Juan Jose Infante’s speech

Bionaturis, co-organizer of the committee along with CTA, took part with the conference titled ‘Second Generation Vaccines: Bionaturis’ Strategy’, in which the CSO, Juan Jose Infante, talked about the main vaccines being developed by Bionaturis so far. Infante has pointed out the relevance of the innovation in the research of vaccines and how they are key elements not only to human, but also to animal health in order to control devastating pandemics. A sustainable and more affordable manufacturing and developing process is essential to guarantee a broad access to high-benefit vaccines, something that Bionaturis gets with its platform FLYLIFE.

Corporacion Tecnologica of Andalusia (CTA) is a private foundation promoted by the […]

Business Angels getting closer to Spanish newborn companies

New Entrepreneurial Act -passed by the Spanish Congress last July- supports the figure of the ‘Business Angels’, private investors that, in group or individually, invest on the growth of a company which is usually located around them. In recent years, this way of funding has meant an important incentive for Small and Medium-Sized Enterprises (SMEs) and entrepreneurs against the problems found nowadays in the traditional systems of bank funding.

Thanks to this new act (still to be approved by the Senate) ‘Business Angels’ will have twenty per cent tax reduction from Income Tax with a maximum discount of 50,000 Euros per year.

The extension of limited fees for self-employed and supporting measures to stimulate bank loans to companies are other measures included in the new act.

If you want to know the act in detail, please click here

Vaccines: the best mankind defense

A brief overview to the history of mankind shows the importance of vaccines and, therefore, of preventive medicine research. Although other threats exist nowadays, thanks to science and the development of new manufacturing platform of vaccines as FLYLIFE of Bionaturis, the world is better prepared than ever to halt the spread of either new or the resurgence of some of the most devastating pandemic episodes in history such as the Black Death, flu or smallpox. The invaluable effort of a lot of researchers and experts has it made possible along centuries that these huge pandemics have become history.

Click here to know how it has been achieved

Families bet on the Spanish Stock Market

The last report about Property Distribution of quoted Spanish stocks that is made annually by BME reveals that there are more and more families that decide to invest on the Stock Market. Actually, a fourth part of the shares are now in the hands of these investor families, four points more that only a year ago and the highest percentage since nearly a decade.

This rise has been visible since 2008 and has meant a net invest in quoted shares of more than €16,000 million at 2012. Some of the reasons of that trend are the drop of the real-state sector, the downward adjustments of quotations during the crisis or the possibility of choosing the payment in stocks instead of cash.

Bionaturis (ticker BNT) has been quoting at the MAB since January 2012.

Clik here for more information

Lines of our CEO, Víctor Infante, about Asebio 2012 annual report

Earlier this month of July was presented the annually ASEBIO report, published by the Spanish Biotechnology Companies Association, taken as a reference of the health of the sector in Spain. As conclusions, the press and specialized opinion highlighted the positive increase of the impact of biotechnology in Spanish GDP (7.15%), with an important rise since 2008 (2.98%), along with a growth of 23.7% of employment up to the 202,250 workers and a 26.5% increase in the turnover.

CEO: Without a doubt the big picture is encouraging and especially taking into account the economical context during this growth. This data should serve to ratify that the biotechnology sector is, and must be more and more, one of the driver vectors of growth in any developed country. However a deeper analysis reveals that we are still quite far from the impact that has on other reference countries. To get closer to expected by our country figures, no doubt that we need more “Grifols” and facilitate in everything, and not otherwise, to companies as Grifols can continue growing and acting as a big leader. Spanish biotechnology needs size, muscles, and big leaders that can complete the whole value chain. Each advanced country in our environment has at least one or two reference leading global companies especially in red biotechnology. Spain should launch a strategic plan to have within a reasonable timeframe at least one company among the top 15 in world sales. We have enough raw material, but we should take it as a matter of State and put in place mechanisms and appropriate measures to implement it.


However, it has also pointed out the decline in R&D investment, the first in ten years.

CEO: Well, it´s not a surprising […]

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.